Saturday 17 October 2026
Export MESO’s income statement to Excel — free account
Mesoblast Limited
MESO Healthcare Biotechnology
Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025. Insiders bought in the last twelve months.
13.28
0.67
−4.80%
Follow MESO
| Dec '25 | Dec '24 | Dec '23 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 |
+8 more TTM periods Free account |
| 0.00% | 0.00% | 0.00% | (16.40%) | ||
| 0.00% | 0.00% | 0.00% | (12.30%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (7.18%) | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | (199.57%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 340.52 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (0.82) | |
Free Cash Flow |
(84.36) | (70.01) | (75.87) | (63.58) | |
Capital Expenditures |
(0.83) | (0.38) | (0.31) | (0.31) | |
| Other line items | |||||
Cash ROIC |
(10.14%) | (11.32%) | (10.81%) | (9.32%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 1.32 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 1.28 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 265.13 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 362.47% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 338.27% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 48.73% | |
Interest Coverage |
— | — | — | (1.55) | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.77 | |
Depreciation/Fixed assets |
4.63 | 5.06 | 0.00 | 3.03 | |
Capex/Depreciation |
(0.10) | (0.07) | 0.00 | (0.08) | |
Revenue per Share |
— | — | — | 0.10 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (0.81) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.04 |
Columns are period end dates